Anita Shaffer


FDA to Reassess Accelerated Immunotherapy Approvals

March 12, 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Shorter Adjuvant Chemo in Colon Cancer Is Effective, Reduces Neuropathy Risk

June 05, 2017

According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.

Trial Examines Triplet Regimen in Ovarian Cancer

February 14, 2017

In a current phase II/III clinical trial for patients with advanced, recurrent, platinum-resistant ovarian cancer, the novel agent fasbretablin tromethamine is combined with bevacizumab (Avastin) and either paclitaxel or pegylated liposomal doxorubicin.